Role of cytosolic calcium-dependent phospholipase A2 in Alzheimer's disease pathogenesis

Molecular Neurobiology

Volumn 45, Issue 3, 2012, Pages 596-604

  Gentile, M T ^a   Reccia, M G ^a   Sorrentino, P P ^c   Vitale, E ^d   Sorrentino, G ^g,h   Puca, A A ^e,f   Colucci D'Amato, L ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d CNR   (Italy)

^e IRCCS MULTIMEDICA   (Italy)

^f UNIVERSITY OF SALERNO   (Italy)

^g UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^h Istitituto di Diagnosi e Cura Hermitage Capodimonte   (Italy)

Author keywords

Alzheimer's disease; Inflammation; Neurodegeneration; PhospholipaseA2; Amyloid

Indexed keywords

CALCIUM; CYTOSOLIC PHOSPHOLIPASE A2;

ALZHEIMER DISEASE; ANIMAL; BIOLOGICAL MODEL; CENTRAL NERVOUS SYSTEM; DRUG ANTAGONISM; ENZYMOLOGY; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; REVIEW;

ALZHEIMER DISEASE; ANIMALS; CALCIUM; CENTRAL NERVOUS SYSTEM; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; PHOSPHOLIPASES A2, CYTOSOLIC;

EID: 84867483609     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-012-8279-4     Document Type: Article

References (85)

1. Bronfman FC, Soto C, Tapia L, Tapia V, Inestrosa NC (1996) Extracellular matrix regulates the amount of the beta-amyloid precursor protein and its amyloidogenic fragments. J Cell Physiol 166(2):360-369
2. Gotz J, Eckert A, Matamale M, Ittner LM, Liu X (2011) Models of Aβ toxicity in Alzheimer's disease. Cell Mol Life Sci 68 (20):3359-3375
3. Goedert M, Spillantini MG (2011) Pathogenesis of the tauopathies. J Mol Neurosci 45:425-431
4. Nizzari M, Barbieri F, Gentile MT, Passarella D, Caorsi V, Diaspro A, Taglialatela M, Pagano A, Colucci-D'Amato L, Florio T, Russo C (2012) Amyloid-β protein precursor regulates phosphorylation and cellular compartmentalization of microtubule associated protein Tau. J Alzheimer's Dis 29(1):211-227
5. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356
6. Selkoe DJ (1998) The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 8:447-453
7. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR et al (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21:383-421
8. McGeer EG, McGeer PL (2003) Inflammatory processes in Alzheimer's disease. Prog Neurophsycopharmacol Biol Psychiatry 27:741-749
9. Wyss-Coray T (2006) Inflammation in Alzheimer's disease: driving force, bystander or beneficial response? Nat Med 12:1005-1015
10. Lee YJ, Han SB, Nam SY, Oh KW, Hong JT (2010) Inflammation and Alzheimer's disease. Arch Pharm Res 33:1539-1550
11. Wyss-coray T, Muche L (2002) Inflammation in neurodegenerative disease: a double-edge sword. Neuron 35(3):419-432
12. Burke JE, Dennis EA (2009) Phospholipase A2 biochemistry. Cardiovasc Drugs Ther 23(1):49
13. Rapoport SI (1999) In vivo fatty acid incorporation into brain phospholipid in relation to signal transduction and membrane remodelling. Neurochem Res 24:1403-1415
14. Leslie CC (2004) Regulation of arachidonic acid availability for eicosanoid production. Biochem Cell Biol 82:1-17
15. Burke JE, Dennis EA (2009) Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res 50:S237-S242
16. Mariggiò S, Sebastià J, Filippi BM, Iurisci C, Volonté C, Amadio S, De Falco V, Santoro M, Corda D (2006) A novel pathway of cell growth regulation mediated by a PLA2alpha-derived phosphoinositide metabolite. FASEB J 20(14):2567-2569
17. Muralikrishna AR, Hatcher JF (2006) Phospholipase A2, reactive oxygen species and lipid peroxidation in cerebral ischemia. Free Radic Biol Med 40(3):376-387
18. Kalyvas A, Baskakis C,MagriotiV, Constantinou-KokotouV, Stephens D, López-Vales R, Lu JQ, Yong VW, Dennis EA, Kokotos G, David S (2009) Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis. Brain 132 (Pt 5):1221-1235
19. Lee HJ, Bazinet RP, Rapoport SI, Bhattacharjee AK (2010) Brain arachidonic acid cascade enzymes are upregulated in a rat model of unilateral Parkinson disease. Neurochem Res 35(4):613-619
20. Farooqui AQA, Ong WY, Horrocks LA (2006) Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol Rev 58:591-620
21. Schaloske RH, Dennis EA (2006) The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta 1761:1246-1259
22. Touqui L, Alaoui-El-Azher M (2001) Mammalian secreted phospholipase A2 and their pathophysiological significance in inflammatory diseases. Curr Mol Med 1(6):739-754
23. Sun GY, Shelat PB, Jensen MB, He Y, Sun AY, Simonyi A (2010) Phospholipase A2 and inflammatory responses in central nervous system. Neuromolecular Med 12(2):133-148
24. Larsson Forsell PK, Kennedy BP, Claesson HE (1999) The human calcium-independent phospholipase A2 gene multiple enzymes with distinct properties from a single gene. Eur J Biochem 262 (2):575-585
25. Basselin M, Rosa AO, Ramadan E, Cheon Y, Chang L, Chen M, Greenstein D, Wohltmann M, Turk J, Rapoport SI (2010) Imaging decreased brain docosahexaenoic acid metabolism and signaling in iPLA2(2)β (VIA)-deficient mice. J Lipid Res 51(11):3166-3173
26. Ghosh M, Tucker DE, Burchett SA, Leslie CC (2006) Properties of the group IV phospholipase A2 family. Prog Lipid Res 45(6):487-510
27. Karabina SA, Gora S, Atout R, Ninio E (2010) Extracellular phospholipases in atherosclerosis. Biochimie 92(6):594-600
28. Abe A, Hiraoka M, Wild S, Wilcoxen SE, Paine R 3rd, Shayman JA (2004) Lysosomal phospholipase A2 is selectively expressed in alveolar macrophages. J Biol Chem 279(41):42605-42611
29. Shayman JA, Kelly R, Kollmeyer J, He Y, Abe A (2011) Group XV phospholipase A, a lysosomal phospholipase A. Prog Lipid Res 50(1):1-13
30. Lambeau G, Gelb MH (2008) Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem 77:495-520
31. Baek SH, Kwon TK, Lim JH, Lee YJ, Chang HW, Lee SJ, Kim JH, Kwun KB (2000) Secretory phospholipase A2-potentiated inducible nitric oxide synthase expression by macrophages requires NF-kappa B activation. J Immunol 164(12):6359-6365
32. Chalbot S, Zetterberg H, Blennow K, Fladby T, Grundke-Iqbal I, Iqbal K (2009) Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity is increased in Alzheimer's disease. Clin Chem 55(12):2171-2179
33. Sharp JD, White DL (1993) Cytosolic PLA2: mRNA levels and potential for transcriptional regulation. J Lipid Mediat 8(3):183-189
34. Katsuki H, Okuda S (1995) Arachidonic acid as a neurotoxic and neurotrophic substance. Prog Neurobiol 46(6):607-636
35. Matsuzawa A, Murakami M, Atsumi G, Imai K, Prados P, Inoue K, Kudi I (1996) Release of secretory phospholipase A2 from rat neuronal cells and is possible function in the regulation of catecholamine secretion. Biochem J 318:701-709
36. Hanasaki K, Arita H (2002) Phospholipase A2 receptor: a regulator of biochemical functions of secretory phospholipase A2. Prostaglandins Other Lipid Mediat 68-69:71-82
37. Matsuzawa A, Murakami M, Atsumi G, Imai K, Prados P, Inoue K, Kudo I (1996) Release of secretory phospholipase A2 from rat neuronal cortical cells and its possible function in the regulation of catecholamine secretion. Biochem J 318:701-709
38. Ikeno Y, Konno N, Cheon SH, Bolchi A, Ottonello S, Kitamoto K, Arioka M (2005) Secretory phospholipases A2 induce neurite outgrowth in PC12 cells through lysophosphatidylcholine generation and activation of G2A receptor. J Biol Chem 280(30):28044-28052
39. Beck G, Sugiura Y, Shinzawa K, Kato S, Setou M, Tsujimoto Y, Sakoda S, Sumi-Akamaru H (2011) Neuroaxonal dystrophy in calcium-independent phospholipase A2β deficiency results from insufficient remodeling and degeneration of mitochondrial and presynaptic membranes. J Neurosc 31(31):11411-11420
40. Chang JY, Tsai PF (2009) IL-6 release from mouse glia caused by MeHg requires cytosolic phospholipase A2 activation. Neurosci Lett 461(2):85-89
41. Alberghina M (2010) Phospholipase A(2): new lessons from endothelial cells. Microvasc Res 80(2):280-285
42. Murakami M, Taketomi Y, Miki Y, Sato H, Hirabayashi T, Yamamoto K (2011) Recent progress in phospholipase A2 research: from cells to animals to humans. Prog Lipid Res 50(2):152-192
43. Bosetti F (2007) Arachidonic acid metabolism in brain physiology and pathology: lessons from genetically altered mouse models. J Neurochem 102(3):577-586
44. Bao F, Wicklund L, Lacor PN, Klein WL, Nordberg A, Marutle A (2012) Different β-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiol Aging 33(4):825
45. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer's disease. Lancet 377(9770):1019-1031
46. Zhang YW, Thompson R, Zhang H, Xu H (2011) APP processing in Alzheimer's disease. Mol Brain 4:3
47. Kisilewsky R (1998) Amyloid beta theads in the fabric of Alzheimer's disease. Nat Med 4:772-773
48. Sutcliffe JG, Hedlund PB, Thomas EA, Bloom FE, Hilbush BS (2011) Peripheral reduction of β-amyloid is sufficient to reduce brain β-amyloid: implications for Alzheimer's disease. J Neurosci Res 89(6):808-814
49. Sagare AP, Deane R, Zetterberg H, Wallin A, Blennow K, Zlokovic BV (2011) Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease. J Alzheimers Dis 24(1):25-34
50. Eisele YS, Obermüller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, Walker LC, Staufenbiel M, Heikenwalder M, Jucker M (2010) Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 330(6006):980-982
51. Zlokovic BV (2005) Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 28:202-208
52. Poulet R, Gentile MT, Vecchione C, Distaso M, Aretini A, Fratta L, Russo G, Echart C, Maffei A, De Simoni MG, Lembo G (2006) Acute hypertension induces oxidative stress in brain tissues. J Cereb Blood Flow Metab 26(2):253-262
53. Gentile MT, Poulet R, Di Pardo A, Cifelli G, Maffei A, Vecchione C, Passarelli F, Landolfi A, Carullo P, Lembo G (2009) Betaamyloid deposition in brain is enhanced in mouse models of arterial hypertension. Neurobiol Aging 30(2):222-228
54. Lee JC, Simonyi A, Sun AY, Sun GY (2011) Phospholipases A2 and neural membrane dynamics: implications for Alzheimer's disease. J Neurochem 116(5):813-819
55. McClure RJ, Kanfer JN, Panchalingam K, Klunk WE, Pettegrew JW (1995) Alzheimer's disease: membrane-associated metabolic changes. Ann N Y Acad Sci 747:110-124
56. Nitsch RM, Blusztain JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ (1992) Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci 89:1671-1675
57. Svennerholm L, Gottfries G (1994) Membrane lipids, selectively diminished in Alzheimer's brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late onset form (type II). J Neurochem 62:1039-1047
58. Wells K (1995) Neural membrane phospholipids in Alzheimer disease. Neurochem Res 20:1329-1333
59. Brown GG, Levine SR, Gorell JM, Pettegrew JW, Gdowsky JW, Bueri JA, Helpern JA, Welch KM (1989) In vivo 31P NMR profiles of Alzheimer's disease and multiple sub cortical infarct dementia. Neurology 39(11):1423-1427
60. Singh IN, Sorrentino G, Kanfer JN (1996) Amyloid beta protein (25-35) activation of phospholipase A2 in LA-N-2 cells. Alzheimer's Res 2:121-128
61. Nicotra A, Lupo G, Giurdanella G, Anfuso CD, Ragusa N, Tirolo C, Marchetti B, Alberghina M (2005) MAPKs mediate the activation of cytosolic phospholipase A2 by amyloid beta (25-35) peptide in bovine retina pericytes. Biochim Biophys Acta 1733(2-3):172-186
62. Kriem B, Sponne I, Fifre A, Malaplate-Armand C, Lozac'h-Pillot K, Koziel V, Yen-Potin FT, Bihain B, Oster T, Olivier JL, Pillot T (2005) Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid-beta peptide. FASEB J 19(1):85-87
63. Gentile MT, Vecchione C, Maffei A, Aretini A, Marino G, Poulet R, Capobianco L, Selvetella G, Lembo G (2004) Mechanisms of soluble beta-amyloid impairment of endothelial function. J Biol Chem 279(46):48135-48142
64. Shelat PB, Chalimoniuk M, Wang JH, Strosznajder JB, Lee JC, Sun AY, Simonyi A, Sun GY (2008) Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. J Neurochem 106(1):45-55
65. He Y, Cui J, Lee JC, Ding S, Chalimoniuk M, Simonyi A, Sun AY, Gu Z, Weisman GA, Wood WG, Sun GY (2011) Prolonged exposure of cortical neurons to oligomeric amyloid-β impairs NMDA receptor function via NADPH oxidase-mediated ROS production: protective effect of green tea (-)-epigallocatechin-3-gallate. ASN Neuro 3(1):e00050
66. Colucci-D'Amato L, Perrone Capano C, di Porzio U (2003) Chronic activation of ERK1/2 and neurodegeneration. Bioessay 37:925
67. Fiala M, Liu QN, Sayre J, Pop V, Brahmandam V, Graves MC, Vinters HV (2002) Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier. Eur J Clin Invest 32(5):360-371
68. Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, Halabisky B, Cissé M, Scearce-Levie K, Cheng IH, Gan L, Palop JJ, Bonventre JV, Mucke L (2008) Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci 11(11):1311-1318
69. Sanchez-Mejia RO, Mucke L (2010) Phospholipase A2 and arachidonic acid in Alzheimer's disease. Biochim Biophys Acta 1801 (8):784-790
70. Kanfer JN, Sorrentino G, Sitar DS (1998) Phospholipases as mediator of amyloid beta peptide neurotoxicity. Neurosci Lett 257:93-96
71. Garnham BM, Fitzpatrick-Wong S, Schunack W, Nürnberg B, Sorrentino G, Parkinson FE, Gasparini L, Racchi M, Binetti G, Trabucchi M, Solerte SB, Alkon D, Etcheberrigaray R, Gibson G, Blass J, Paoletti R, Govoni S (1998) Peripheral markers in testing pathophisiological hypotheses and diagnosing Alzheimer's disaese. FASEB J 12:17-35
72. Schaeffer EL, Gattaz WF (2007) Requirement of hippocampal phospholipase A2 activity for long term memory retrieval in rats. J Neural Trasm 114:379-385
73. Smesny S, Stein S, Willhardt I, Lasch J, Sauer H (2008) Decreased phospholipase A2 activity in cerebrospinal fluid of patients with dementia. J Neural Transm 115(8):1173-1179
74. Pruzanski W (2005) Phospholipase A2: quo vadis? J Rheumatol 32:400-401
75. Lizano S, Domont G, Perales J (2003) Natural phospholipase A(2) myotoxin inhibitor proteins from snakes, mammals, and plants. Toxicon 42:963-977
76. Cunningham TJ, Souayah N, Jameson B, Mitchell J, Yao L (2004) Systemic treatment of cerebral cortex lesions in rats with a new secreted phospholipase A2 inhibitor. J Neurotrauma 21:1683-1691
77. Trimble LA, Street IP, Perrier H, Tremblay NM, Weech PK, Bernstain MA (1993) NMR structural studies of the tight complex between a tryfluoromethyl ketone inhibitor and the 85-kDA human phospholipase A2. Biochemistry 32(47):12560-12565
78. Riendeau D, Guay J, Weech PK, Lalibertè F, Yergey J, Li C, Desmarais S, Perrier H, Liu S, Nicoll-Griffith D (1994) Arachidonyl tryfluoromethyl ketone, a potent inhibitor of 85-kDA phospholipase A2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. J Biol Chem 269(22):15619-15624
79. Mouchlis VD, Barbayianni E, Mavromoustakos TM, Kokotos G (2011) The application of rational design on phospholipase A2 inhibitors. Curr Med Chem 18(17):2566-2582
80. Puca AA, Andrew P, Novelli V, Anselmi CV, Somalvico F, Cirillo NA, Chatgilialoglu C, Ferreri C (2008) Fatty acid profile of erythrocyte membranes as possible biomarker of longevity. Rejuvenation Res 11(1):63-72
81. Fukaya T, Gondaira T, Kashiyae Y, Kotani S, Ishikura Y, Fujikawa S, Kiso Y, Sakakibara M (2007) Arachidonic acid preserves hippocampal neuron membrane fluidity in senescent rats. Neurobiol Aging 28:1179-1186
82. Puca AA, Chatgilialoglu C, Ferreri C (2008) Lipid metabolism and diet: possible mechanisms of slow aging. Int J Biochem Cell Biol 40(3):324-333
83. Hulbert AJ (2008) Explaining longevity of different animals: is membrane fatty acid composition the missing link? Age (Dordr) 30 (2-3):89-97
84. Kotani S, Sakaguchi E,Warashina S, Matsukawa N, Ishikura Y, Kiso Y, Sakakibara M, Yoshimoto T, Guo J, Yamashima T (2006) Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 56(2):159-164
85. Katsuki H, Okuda S (1995) Arachidonic acid as a neurotoxic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 56(2):159-164